Open AccessFirst prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN
Author(s) -
Heera Jayvant,
Valluri Srinivas,
Craig Charles,
Fang Annie,
Thomas Neal,
Dan Meyer Ralph,
Demarest James
Publication year - 2014
Publication title -
journal of the international aids society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.724
H-Index - 62
ISSN - 1758-2652
DOI - 10.7448/ias.17.4.19519
Subject(s) - maraviroc , tropism , medicine , ccr5 receptor antagonist , genotype , v3 loop , virology , tissue tropism , human immunodeficiency virus (hiv) , randomized controlled trial , prospective cohort study , viral load , immunology , virus , biology , genetics , antibody , chemokine , receptor , chemokine receptor , epitope , gene
MODERN (A4001095) was the first prospective phase 3 study comparing genotype vs phenotype (Trofile™) tropism assessments. Materials and Methods Treatment‐naïve adults with HIV‐1 RNA >1000 copies/mL were randomized 1:1 at screening to either genotype or Trofile for tropism assessment. Genotype was determined using the geno2pheno algorithm to assess triplicate HIV‐1 gp120 V3 loop sequences (plasma); false‐positive rate=10%. R5‐virus‐infected subjects were then randomized 1:1 to receive Maraviroc (MVC) 150 mg QD or Truvada 200/300 mg QD each with DRV/r 800/100 mg QD. Tropism of screening samples from enrolled subjects was also retrospectively determined using the alternate testing method. Positive predictive values (PPV) were estimated by%R5 subjects with Week 48 HIV‐1 RNA < 50 c/mL. PPV for each assay was estimated using the response rate among those randomized to that assay and using model‐based response estimates in those with R5 by that assay (at screening or retest). Results The observed response rate was 146/181 (80.7%) for genotype vs 160/215 (74.4%) for Trofile (stratification adjusted difference=6.9%, 95% CI 1.3% to 15%). The model‐based estimates of PPV (±SE) were 79.1% (±2.42) and 76.3% (±2.38), respectively (difference = 2.8%, 95% CI −2.1% to 7.2%). There was no difference in response rate between assays in the Truvada arm (observed difference=− 0.1%, 95% CI −6.8% to 6.6%). Most enrolled subjects had R5 results at screening using both assays (285/396 (72%)), and of these subjects, 79.3% (226/285) had HIV‐1 RNA <50 c/mL at week 48 (Table 1). The few subjects classified as non‐R5 by the alternate assay had similar virologic responses to the concordant R5 group. Conclusion There was a higher MVC response rate and model‐based positive predictive value with genotype compared to Trofile, but this difference did not reach statistical significance. The majority of subjects had concordant R5 tropism results. Either phenotype or genotype can effectively predict MVC response.